Among commonly used HDAC inhibitors, such as trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and nicotinamide (NAM), SAHA has been approved in clinical trials for cancer treatment (84, 85). Here, HDAC9 is linked to cancer.